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Abstract
Because of the lack of full characterization of tumor associated antigens for solid tumors, whole
antigen use is a convenient approach to tumor vaccination. Tumor RNA and apoptotic tumor cells
have been used as a source of whole tumor antigen to prepare dendritic cell (DC) based tumor
vaccines, but their efficacy has not been directly compared. Here we compare directly RNA
electroporation and pulsing of DCs with whole tumor cells killed by ultraviolet (UV) B radiation
using a convenient tumor model expressing human papilloma virus (HPV) E6 and E7 oncogenes.
Although both approaches led to DCs presenting tumor antigen, electroporation with tumor cell
total RNA induced a significantly higher frequency of tumor-reactive IFN-gamma secreting T cells,
and E7-specific CD8+ lymphocytes compared to pulsing with UV-irradiated tumor cells. DCs
electroporated with tumor cell RNA induced a larger tumor infiltration by T cells and produced a
significantly stronger delay in tumor growth compared to DCs pulsed with UV-irradiated tumor
cells. We conclude that electroporation with whole tumor cell RNA and pulsing with UV-irradiated
tumor cells are both effective in eliciting antitumor immune response, but RNA electroporation
results in more potent tumor vaccination under the examined experimental conditions.
Introduction
Because tumor-associated antigens are not well character-
ized for the majority of human tumors, polyvalent vac-
cines prepared with whole tumor antigen are an attractive
approach to induce tumor vaccination [1,2]. Recent
advances in generation and manipulation of DCs provide
opportunities to design powerful tumor vaccines. DCs are
ideal vehicles for polyvalent tumor vaccination, as they
readily process and present tumor antigen taken up from
dying tumor cells.
DCs pulsed with apoptotic tumor cells have been used
successfully to induce tumor vaccination [3-6,6-12].
Although controversy surrounds the ability of necrotic
versus apoptotic tumor cells to serve as a source of multi-
valent antigen to pulse DCs [10,13-15], UVB irradiation
has been shown to result in a mixed population of apop-
totic and necrotic tumor cells [16]. Tumor cells exposed to
lethal ultraviolet-B (UVB) radiation have been shown to
provide a suitable source of tumor antigen for DCs
[16,17]. For example, UV-irradiated primary tumor cells
provide sufficient tumor antigen to elicit expansion of
tumor-reactive autologous T cells ex vivo in patients with
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advanced ovarian cancer [17], suggesting that this
approach can be used clinically to induce therapeutic vac-
cination.
Several reports have described the use of tumor-extracted
RNA as source of tumor antigen for the preparation of
DCs and have indicated its potential use for antigen-spe-
cific or polyvalent tumor vaccination in the absence of
identified tumor antigens [18-23]. Such approach may
address important limitations in the procurement of
tumor antigen, as primary tumor cell cultures are not fea-
sible for a large number of patients. Although the feasibil-
ity and efficacy of electroporation of DCs with RNA for the
preparation of polyvalent tumor vaccines has been con-
vincingly demonstrated, a direct comparison of DC vac-
cines prepared with tumor RNA versus dying whole tumor
cells has not been performed.
In this study, we compared tumor RNA to apoptotic
tumor cells as a source of tumor antigen to generate a DC-
based vaccine against tumors expressing the early gene
products E6 and E7 of the human papilloma virus (HPV).
We report that the use of tumor RNA as a source of tumor
antigen is valuable alternative and superior to UV-irradi-
ated tumor cells.
Materials and methods
Cell lines
TC-1, cell line was a generous gift from Dr. Yvonne Pater-
son, University of Pennsylvania. TC-1 cells were main-
tained in RPMI (Invitrogen, Carlsbad, CA) supplemented
with L-glutamine (2 mM); penicillin (100 U/ml); strepto-
mycin (100 µg/ml); 10% fetal bovine serum (FBS), and
geneticin (1 mg/ml).
ID8, a cell line derived from spontaneous in vitro malig-
nant transformation of C57BL/6 mouse ovarian surface
epithelial cells, was a generous gift from Dr. Paul F. Ter-
ranova, University of Kansas [24]. ID8 cells were main-
tained in DMEM medium (Invitrogen) supplemented
with 4% FBS, penicillin, streptomycin, insulin (5 µg/ml),
transferrin (5 µg/ml), and sodium selenite (5 ng/ml, all
Roche, Indianapolis, IN) in a 5% CO2 atmosphere at
37°C. An ID8 cell line expressing the HPV16 E6 and E7
antigens was generated by transducing ID8 cells with the
retroviral vector LXSN16E6E7 (American Type Culture
Collection, Rockville, MD, donated by Dr. D. Galloway),
which encodes the HPV16 E6 and E7 genes, as well as the
neomycin phosphotransferase gene. The PA317 cell line
was used to generate the retroviral vectors as previously
described [25]. Selection of ID8 cells transduced with E6
and E7 (ID8-E6/7) or ID8 cells transduced with a control
retroviral vector (LXSN) was achieved under neomycin
pressure (1 mg/ml) [25]. The murine L929 (ATCC)
immortalized cell line was grown in RPMI 1640 with 10%
FBS and penicillin/streptomycin. All lines tested negative
for Mycoplasma by PCR.
Animals and tumors
Six to eight week old female C57BL/6 (H-2Kb) and BALB/
c (H-2Kd) mice (Charles River Laboratories, Wilmington,
MA) were used in protocols approved by the Institutional
Animal Care and Use Committee and the University of
Pennsylvania. TC-1 tumors were generated in C57BL/6
mice by s.c. inoculation of 2 × 104 TC-1 cells in 0.2 ml of
PBS. Tumors were detectable ten days later and were
measured weekly using a Vernier caliper. Tumor volumes
were calculated by the formula V= 1/2 L × W2, where L is
length (longest dimension) and W is width (shortest
dimension). For some in vivo studies, CD8+ cells were
depleted with rat anti-mouse CD8 (MCA1768XZ) and
CD4+ cells with rat anti-mouse CD4 (MCA1767XZ) (both
Serotec, Raleigh, NC). The antibodies were administered
intravenously (100 µg/animal) on the day of tumor injec-
tion and a second dose one week later.
Generation of bone marrow-derived DCs
Murine dendritic cells were generated from bone marrow
precursor cells with recombinant murine granulocyte-
macrophage colony-stimulating factor (GM-CSF; Pepro-
tech, Rocky Hill, NJ; 20 ng/ml) as described previously
[26]. Cells were counted using Trypan blue. Differentia-
tion into immature DCs was documented through flow
cytometry detection of CD80, CD86 and major histocom-
patibility complex class II (MHC-II). DC maturation was
induced by culturing cells in RPMI media under standard
conditions in the presence of 10 ng/ml murine GM-CSF
supplemented with 0.1 µg/ml lipopolysaccharide (LPS,
Sigma Chemical Co, Saint Louis, MO) and 20 ng/ml
tumor necrosis factor-alpha (TNF-α, Peprotech).
DC electroporation with tumor RNA
Total cellular RNA was extracted from TC-1 cells using
TRIzol Reagent (Invitrogen). Cells grown in 75 cm2 flasks
were resuspended and lysed using TRIzol reagent. Chloro-
form (0.2 ml per ml of TRIzol reagent) was added and
incubated at room temperature for 2 min. The samples
were centrifuged at 12,000 × g for 15 min at 4°C, and the
aqueous phase was transferred to a new tube. Cold isopro-
panol was added at 0.5 ml per ml TRIzol reagent to pre-
cipitate RNA. Following 10 min incubation at room
temperature the samples were centrifuged at 12,000 × g
for 10 min at 4°C. The RNA pellet was washed once with
70% DEPC-ethanol and centrifuged at 7500 × g for 5 min.
The pellet was briefly dried and dissolved in DEPC water.
The quality and quantity of the total RNA was checked
using RNA Nano LabChip® (Agilent Technologies, Palo
Alto, CA) according to the protocol provided. Two million
DCs were resuspended with the appropriate amount of
total TC-1 RNA in a 0.2-cm cuvette and electroporatedJournal of Translational Medicine 2008, 6:21 http://www.translational-medicine.com/content/6/1/21
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using Gene Pulser II (BIO-RAD Laboratories, Hercules,
CA) under different voltage and capacitance settings. DCs
electroporated in the absence of TC-1 RNA (mock) were
used as controls for some experiments.
DC pulsing with apoptotic tumor cells
Subconfluent cultures of TC-1 cells were rinsed twice in
phosphate buffer saline (PBS) and exposed to ultraviolet-
B (UVB) radiation at various doses up to 1500 µW/cm2 for
various times. Apoptosis at 24 hours was quantified by
flow cytometry detection of annexin-V staining using the
TACS™ Annexin-Biotin Apoptosis detection kit (R&D Sys-
tems, Minneapolis, MN) and confirmed with the ApopTag
peroxidase in situ detection kit (Intergen, Purchase, NY)
and the Apoptotic DNA-Ladder Kit (Roche), according to
the manufacturers' instructions. Twenty-four hours after
UVB radiation tumor cells were incubated with immature
DCs at a 2:1 ratio (tumor cells, DCs). Twenty-four hours
later, TNF-α (Peprotech; 20 ng/ml) and LPS (0.1 µg/ml)
were added for additional 48 hours. DCs were harvested,
rinsed and counted by trypan blue exclusion. In some
experiments, radiated tumor cells were labeled with
PKH26 fluorescent dye (Sigma; 5 µM) for 5 min at room
temperature. RPMI supplemented with 10% FBS was
added to stop the reaction and cells were rinsed three
times prior to using them for pulsing DCs.
Animal vaccination
Animals received one intraperitoneally (i.p.) and then
twice subcutaneously (s.c.) seven days apart, DCs (5 × 105
per dose) electroporated with TC-1 RNA or loaded with
TC-1 cells killed by UVB and incubated with TNF-α (20
ng/ml) and LPS (0.1 µg/ml) were injected once. DCs.
Control animals were injected with DCs mock electropo-
rated and matured with TNF-α and LPS. Animals were
challenged with tumor cells seven days after the last DC
vaccination.
Flow cytometry
Cells were subjected to four-color flow cytometry on a
FACSCalibur flow cytometer using CellQuest 3.2.1f1 soft-
ware (Becton Dickinson, San Jose, CA). Non-specific
staining was blocked with anti-CD16/CD32 antibody (Fc
block, 2.4G2; BD Pharmingen; San Diego, CA). Fluoro-
chrome-conjugated monoclonal antibodies against CD3
(17A2), CD8 [53–67], CD11c (HL3), CD80 (16-10A1),
CD86 (GL1), MHC-I (H-2 kb/H-2Db), MHC-II (KH74; all
BD Pharmingen, San Diego, CA) were used at 1:100 dilu-
tion. PE-conjugated H2-Db RAHYNIVTF tetramer recog-
nizing a dominant MHC-I epitope of E7 antigen [27] was
a kind gift of Dr. Yvonne Paterson. Rabbit anti-HPV-16 E6
(N-17) and E7 (ED-17) antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA) were used at 1:100 dilution.
Proliferation assays
For mixed leukocyte reactions C57BL/6 DCs were electro-
porated with TC-1 RNA (50 µg/106 DCs) or loaded with
TC-1 cells killed with UVB; incubated with TNF-α and LPS
for 48 h; washed twice with PBS; and subjected to gamma-
irradiation (20 Gy). DCs were seeded in 96-well round-
bottom plates at various dilutions in RPMI containing
10% FBS. BALB/c spleen lymphocytes were procured as
described [28]. Constant number of BALB/c lymphocytes
(1 × 105 cells/well) were incubated with irradiated C57BL/
6 DCs at increasing ratios (DC: lymphocytes) for 5 days at
37°C. [3H]thymidine (NEN Life Science, Boston, MA, 1
µCi/well) was added for 18 hours at 37°C. Samples were
recovered on glass fiber filters and analyzed with a
Microbeta Trilux (Perkin Elmer Wallac, Inc., Gaithersburg,
MD). Each experimental value was determined three
times. For some experiments, splenocytes from vaccinated
animals were cultured with gamma-irradiated (20 Gy)
tumor cells in the presence of 20 U/ml of recombinant
murine IL-2 (Peprotech). After 5 days 1 µCi/well of
[3H]thymidine was added for 18 hours at 37°C.
Chemotaxis assay
Migration of DCs towards murine macrophage inflamma-
tory protein (MIP)-3α or MIP-3β (R&D Systems, Minne-
apolis, MN) was assessed in 96-well chemotaxis chambers
using an 8 µm-pore nitrocellulose membrane (Neuro-
probe, Gathersburg, MD) [29]. Pyrogen-free RPMI 1640
containing 1% BSA was used as chemotactic media.
Results are presented as chemotactic index (CI), defined
as fold increase in cell migration in the presence of chem-
otactic factors compared to chemotactic media alone.
Each experiment was performed in triplicate.
IFN-γ ELISPOT
ELISPOT was performed as previously described [28]. We
used purified anti-mouse IFN-γ (R4-6A2) for capture and
biotin anti-mouse IFN-γ (XMG1.2) (both BD Pharmin-
gen) for detection.
Immunostaining
Solid tumor samples (n = 6 for each experimental group)
were snap-frozen in ornithine carbamyltransferase (OCT,
Tissue Tek, Sakura, Torrance, CA). For immunofluores-
cense analysis, sections were fixed in cold acetone for 10
minutes and sequentially incubated with anti-mouse
CD16/32 antibody (1:100 dilution), FITC-anti-mouse
CD3 (17A2) and biotin-anti-mouse CD8 (53–67, 1:100
dilution, both BD Pharmingen). After incubation with
streptavidin tetramethylrhodamine conjugate (Molecular
Probes, Eugene, OR) (1:200 dilution), sections were
counterstained with 4',6'-diamidino-2-phenylindole
hydrochloride (DAPI) and inspected under the fluores-
cent microscope.Journal of Translational Medicine 2008, 6:21 http://www.translational-medicine.com/content/6/1/21
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For immunofluorescense of DCs following electropora-
tion with TC-1 RNA, electroporated DCs were seeded on
glass coverslips and cultured in RPMI in the presence of
10% FBS and 10 ng/ml GM-CSF for two days. Cells were
fixed with acetone and consecutively stained with anti-
HPV-16 E7 antibody (ED-17, Santa Cruz Biotechnolo-
gies) and anti-rabbit FITC (BD Pharmingen). Slides were
counterstained with DAPI. Images were acquired through
Cool SNAP Pro color digital camera (Media Cybernetics,
Carlsbad, CA). Ten different fields for each sample at ×
400 magnification were evaluated for cell counting.
Immunoprecipitation and Western blot
For E7 immunoprecipitation and Western blot analysis,
ID8-E6/7 and ID8 control cells were lysed in M-Per mam-
malian protein extraction kit (Pierce, Rockford, IL) plus
protease inhibitor cocktail (HALT Protease inhibitor kit,
Pierce). Lysate concentration was determined by the Brad-
ford assay (Biorad; Hercules, CA). Two hundred micro-
grams of extract was subjected to immunoprecipitation
with rabbit anti-HPV16 E7 (ED-17, Santa Cruz Biotech-
nologies). Immunoconjugates were collected on protein
A-agarose (Invitrogen), washed with lysis buffer, and
resolved on 15% acrylamide gels. Proteins were trans-
ferred to polyvinylidene difluoride membranes (Immo-
bilon-P, Millipore) and probed with mouse anti-E7
antibody (clone 8C9, Zymed Labs Inc., San Fransisco,
CA). Sheep anti-mouse IgG-HRP (NA93IV, Amersham
Biosciences, Buckinhamshire, UK) was used as the sec-
ondary reagent. Proteins were visualized by enhanced
chemiluminescence (Lumigen PS-3, Amersham) and
exposure to Kodak X-Omat Blue film.
RT-PCR and Real-Time Quantitative Reverse 
Transcription-PCR
The expression of E6 and E7 was demonstrated using RT-
PCR with the following primers: E6 forward primer (F),
5'-AAA GCA GAC ATT TTA TGC ACC A-3'; E6 reverse
primer (R), 5'-TCA TGC AAT GTA GGT GTA TCT CC -3';
E7 F 5'-CAC GTA GAG AAA CCC AGC TGT A -3'; E7 R 5'-
GTA CCC TCT TCC CCA TTG TT-3'. The RT portion of the
RT-PCR was conducted using SuperScript reverse tran-
scriptase (Invitrogen) at 50°C (10 min). The PCR cycling
was conducted with Taq polymerase for both sequences at
94°C (3 min), 50°C (1 min), and 72°C (1 min) for 40
cycles.
The AbiPrism 7700 Sequence Detection System and SYBR
green I PCR kits (both Applied Biosystems, Foster City,
CA) were used for Real-Time PCR as described previously
[30]. The following primers were used: E6: F 5'-GAC TTT
GCT TTT CGG GAT TTA TGC -3', R 5'-TCA CAC AAC GGT
TTG TTG TAT TGC-3'; E7: F 5'-CTG GAC AAG CAG AAC
CGG ACA-3', R 5'-TGC TTT GTA CGC ACA CCG AA-3'.
We normalized the cDNA load to mouse glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) with primers
GAPDH F 5'-CCT GCA CCA CCA ACT GCT TA-3' and
GAPDH R 5'-CAT GAG TCC TTC CAC GAT ACC A-3'. Data
were expressed as relative units to GAPDH mRNA mole-
cules. Molecules were considered to be present if more
than five copies of mRNA were detected for every 106 cop-
ies of GAPDH mRNA.
Statistical analysis
A two-tailed Student's t-test was applied to determine dif-
ferences between two groups. For multiple comparisons
we performed ANOVA with post-analysis comparisons by
the Tukey-Kramer multiple comparisons test. Non-para-
metric studies were performed by using the Mann-Whit-
ney U test. A value of p < 0.05 was considered significant.
Data are expressed as mean ± SD. Data was analyzed using
Graph Pad Instat software (GraphPad Software, Inc., San
Diego, CA).
Results
Preparation of DCs electroporated with TC-1 cell RNA 
(RNA-DCs)
To test the efficacy of loading DCs with tumor antigen by
RNA electroporation we used TC-1 cells, a mouse adeno-
carcinoma cell line generated by cotransfection of lung
epithelial cells with HPV-16 E6 and E7 genes and H-Ras
[31], which has been used to test E6 and E7-targeted
tumor immunotherapy [32-34]. Reproducible amounts of
total RNA ranging between 20–35 µg RNA/106 cells were
obtained from cultured TC-1 cells (Mean = 27.05, SD =
9.183, N = 10 independent samples). High quality RNA
was procured (Figure 1A), with rRNA ratio (28S/18S)
reproducibly greater than 2.00 (Figure 1B).
To determine the best conditions for RNA electroporation
in our system, bone marrow-derived DCs were electropo-
rated with tumor cell RNA using different capacitance and
voltage settings and 25 µg RNA per 106 DCs, which repre-
sents RNA from approximately one tumor cell per DC.
The reaction was performed in a total volume of 200 µL.
As shown in Figure 1C, the highest expression of E7 anti-
gen in live electroporated DCs, was obtained at 300 V and
150 µF. These settings yielded 50% viability in electropo-
rated DCs, as determined by flow cytometry PI exclusion
analysis (Figure 1D). Similar viability levels were obtained
in DCs electroporated in the absence of RNA (mock, not
shown).
To optimize DC electroporation, we electroporated DCs
with different amounts of TC-1 RNA (5–50 µg/106 DCs)
using the previously determined settings (300 V, 150 µF).
E6-transcripts are longer than E7. As shown in Figure 1E,
high E6 expression was observed only after electroporat-
ing 50 µg TC-1 RNA/106 DCs. Higher RNA amounts did
not result in increased E6 expression (not shown). Elec-Journal of Translational Medicine 2008, 6:21 http://www.translational-medicine.com/content/6/1/21
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Expression of tumor-associated HPV E6 and E7 antigens by bone marrow-derived DCs after RNA electroporation Figure 1
Expression of tumor-associated HPV E6 and E7 antigens by bone marrow-derived DCs after RNA electroporation. (A) Gel-
like image obtained from 10 independent samples of TC-1 RNA analyzed by the Agilent bioanalyzer. (B) Electropherogram of 
sample 1 from A showing ribosomal RNA peaks. (C) Flow cytometry analysis of intracellular E7 expression in CD11c+ cells 24 
hours after electroporation with TC-1 RNA at different voltage and capacitance conditions. Electroporation was performed 
with 25 µg TC-1 RNA/106 DCs (grey): mock electroporated (white). (D) Flow cytometry analysis of DC viability 24 hours after 
electroporation at different conditions of voltage and capacitance. Electroporation was performed with 25 µg TC-1 RNA/106 
DCs. X-axis reflects propidium iodide (PI) staining. (E) Flow cytometry analysis of intracellular E6 and E7 expression in CD11c+ 
cells 24 hours after electroporation with different amounts of TC-1 RNA at 300V and 150 µF. The experiment was repeated 
two times with similar results. (F) Flow cytometry analysis of intracellular E6 and E7 expression in CD11c+ cells 4 days after 
electroporation with 50 µg of TC-1 RNA/106 DCs at 300V and 150 µF. RNA electroporated (white); mock electroporated 
(grey). (G) Immunofluorescence of DCs stained with anti-HPV E7 antibody 24 hours after electroporation with TC-1 cell RNA 
or mock electroporated. Cells were counterstained with DAPI. 200X magnification. All experiments were repeated twice with 
similar results.
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troporation with 50 µg RNA/106 DCs also ensured high
expression of E7-antigen in DCs (Figure 1E). As shown in
Figure 1F, high expression of E6 and E7 protein was
detectable by flow cytometry for at least 4 days after RNA
electroporation with 50 µg of TC-1 RNA/106  DCs.
Immunofluorescence staining confirmed the presence of
E7 protein in the cytoplasm of DCs 24 hours after electro-
poration with 50 µg TC-1 RNA/106 DCs (Figure 1G).
Preparation of DCs pulsed with UV irradiated TC-1 cells 
(UV-DCs)
We tested various doses of ultraviolet-B (UVB) light and
exposure times to identify UVB conditions that kill greater
than 95% of TC-1 cells (not shown). Irradiation with
1500 µW/cm2 UVB for 10 min induced apoptosis in TC-1
cells as assessed by DNA fragmentation detectable by
TUNEL assay (Figure 2A) and DNA laddering (Figure 2B),
while by flow cytometry the majority of cells were
annexin-V positive or propidium iodide and annexin-V
double positive within 24 hours (Figure 2C).
To verify the uptake of UV-irradiated cells by DCs, UV-
irradiated TC-1 cells were labeled with PKH26 fluorescent
dye prior to pulsing of DCs. DCs and UV-irradiated tumor
cells were cocultured for 18 hours to allow the uptake of
tumor cell material by DCs. Cells were then stained with
antibody against CD11c, and CD11c+ DCs were analyzed
for PKH26 expression with flow cytometry. More than
60% of DCs had taken up fluorescent tumor cells (Figure
2D), compared with a background level of 1% in the con-
trol sample containing DCs and UV-irradiated cells
admixed just before analysis (not shown).
Maturation of RNA-DCs and UV-DCs
We assessed whether DCs prepared by RNA electropora-
tion or pulsing with UV-irradiated tumor cells respond
differently to maturation stimuli such as TNF-α and LPS.
Significant surface expression of CD86 and CD80 and
MHC-II molecules was noted in DCs 48 hours post-elec-
troporation with tumor cell RNA, as described above, in
the presence of TNF-α and LPS (Figure 3A). Similarly,
immature DCs incubated with TC-1 cells exposed 24 hour
earlier to lethal dose of UVB radiation upregulated CD80,
CD86 and MHC-II 48 hours post-phagocytosis, in the
presence of TNF-α and LPS (Figure 3B).
Next, we assessed whether DCs electroporated with tumor
cell RNA (RNA-DCs) or pulsed with UV-irradiated tumor
UVB-induced apoptosis of TC-1 cells and maturation of TC-1 antigen-loaded DCs Figure 2
UVB-induced apoptosis of TC-1 cells and maturation of TC-1 antigen-loaded DCs. (A) TUNEL assay of UVB-treated and con-
trol TC-1 cells 24 hours post-irradiation. (B) DNA ladder assay of TC-1 cells 24 hours after irradiation with UVB light. (C) 
Flow cytometry analysis of annexin V in UVB-treated cells 24 hours post-irradiation. (D) Percentage of DCs that have engulfed 
tumor cells, as determined by flow cytometry. DCs were pulsed with cells killed by UVB. Apoptotic tumor cells were labeled 
with PKH26 prior to pulsing. DCs were stained with antibody against CD11c.
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cells (UV-DCs) and matured with TNF-α and LPS differ in
vitro in their ability to induce proliferation of allogeneic
lymphocytes or to migrate towards lymphoid organ
chemokines. Immature DCs were incubated for 48 with
TC-1 cells exposed 24 hours earlier to lethal UVB radia-
tion or were electroporated with tumor cell RNA, as
described above. To minimize differences in the amount
of original tumor antigen used with both loading proce-
dures, DCs were incubated with UVB-irradiated cells at
1:2 ratio (DC, tumor cells) or electroporated with an
equivalent amount of total RNA (50 µg RNA correspond-
ing to 2 × 106 tumor cells per 106 DCs). RNA-DCs stimu-
lated proliferation of allogeneic spleen lymphocytes in a
similar manner to UV-DCs. As expected, unpulsed imma-
ture DCs did not stimulate allogeneic reaction (Figure
3C).
(A) Expression of maturation markers in E7+ CD11c+ gated cells 72 hours after electroporation with TC-1 RNA (50 µg/106  cells) Figure 3
(A) Expression of maturation markers in E7+CD11c+ gated cells 72 hours after electroporation with TC-1 RNA (50 µg/106 
cells). LPS and TNF-α were added to the culture medium 24 hours after electroporation. (white): specific antibody; (grey): iso-
type control. The experiment was repeated two times with similar results. (B) Expression of markers in CD11c+ gated cells 72 
hours after phagocytosis of UVB-irradiated TC-1 cells. LPS and TNF-α were added to the culture medium after 24 hours of 
coincubation. (white): specific antibody; (grey): isotype control. (C) Proliferation of allogeneic BALB/c splenocytes induced by 
C57BL/6 DCs electroporated with TC-1 cell RNA (RNA) or pulsed with UV-irradiated TC-1 cells (UVB). DCs were treated 
with TNF-α and LPS. Data were obtained 48 hours after stimulation of splenocytes and are expressed as the mean ± SEM of 
two experiments with triplicate observations per experiment. (D) Migration of DCs towards MIP-3α or MIP-3β 72 hours after 
electroporation with TC-1 RNA (RNA) or pulsing with UV-irradiated TC-1 cells (UVB). LPS and TNF-α were added to the 
culture medium after 24 hours of coincubation. Chemotactic index is defined as the fold increase in cell migration caused by 
the chemotactic factors. Data are expressed as the mean ± SD of two experiments with quadruplicate observations per exper-
iment.
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A switch in chemokine receptors is a hallmark of DC mat-
uration. Among others, this entails upregulation of CCR7
and downregulation of CCR6 [35]. RNA-DCs and UV-
DCs matured with TNF-α and LPS exhibited similar
migratory properties. As shown in Figure 3D, both DCs
lost the ability to migrate towards macrophage inflamma-
tory protein 3-alpha (MIP3-α), the ligand for CCR6, and
acquired the ability to migrate towards MIP-3β, the ligand
for CCR7.
Development of additional tumor targets expressing HPV-
16 E6 and E7
To further compare tumor vaccination with RNA-DCs and
UV-DCs, we engineered an additional tumor cell line
expressing HPV E6 and E7. We used the syngeneic C57BL/
6 murine ovarian cancer cell line ID8. ID8 cells trans-
duced with the retroviral vector LXSN16E6E7, which
encodes the HPV16 E6 and E7 genes, as well as the neo-
mycin phosphotransferase gene (ID8-E6/7) stably
expressed E6 and E7 mRNAs under genetecin pressure,
Expression of HPV-16 E6 and E7 antigens in retrovirus-transduced ID8 cells Figure 4
Expression of HPV-16 E6 and E7 antigens in retrovirus-transduced ID8 cells. (A) RT-PCR analysis for HPV-16 E6 and E7 tran-
scripts in ID8 cells transduced with HPV-16 E6 and E7 genes; ID8 cells transduced with empty vector (negative control); and 
TC-1 cells (positive control). M: molecular markers. (B) Real-time quantitative PCR analysis of E6 and E7 transcripts in ID8 
cells transduced with HPV-16 E6 and E7 genes and ID8 cells carrying empty vector. (C) Western blot analysis of cell lysate 
showing presence of E6 protein in samples obtained from ID8 E6/7 cells but not in ID8 cells carrying empty vector. M: molec-
ular markers. (D) Flow cytometry analysis of intracellular E6 and E7 proteins in ID8 cells transduced with HPV-16 E6 and E7 
genes. (grey): ID8 E6/7 cells; (white): ID8 cells transduced with empty vector, (dotted line): isotype control. (E) Expression of 
MHC-I by ID8-E6/7 cells. (grey): ID8 E6/7 cells; (white): isotype control.
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compared to ID8 cells transduced with the empty vector
(ID8) (Figure 4A and 4B). Immunoprecipitation followed
by Western blot analysis revealed the presence of E6 pro-
tein in ID8-E6/7 cells but not in ID8 cells transduced with
empty vector (Figure 4C). Moreover, intracellular staining
of ID8 E6/7 cells showed the presence of HPV-16 E6 and
E7 proteins (Figure 4D). As the parental ID8 cell line [36],
ID8-E6/7 cell line expressed MHC class-I molecules (Fig-
ure 4E).
RNA-DCs and UV-DCs are immunogenic in vivo
We compared the efficacy of RNA-DCs and UV-DCs to
induce tumor vaccination. To minimize differences in the
amount of tumor antigen between pulsing procedures,
DCs were incubated with UV-irradiated cells at 1:2 ratio
(DC, tumor cell) or electroporated with an amount of
total RNA equivalent to two tumor cells per DC, as above.
DCs were matured with TNF-α and LPS. Mock DCs were
prepared by electroporation in the absence of tumor RNA
followed by maturation with TNF-α and LPS. Healthy ani-
mals were vaccinated with RNA-DCs or UV-DCs, while
control animals were vaccinated with mock DCs or left
unvaccinated (naïve). Splenocytes isolated from the
above animals were tested for reactivity against E6 and E7
antigens by incubating them with apoptotic TC-1, ID8-
E6/7, ID8 or L-929 cells.
When incubated with TC-1 cells, splenocytes from ani-
mals vaccinated with RNA-DCs proliferated significantly
more than splenocytes from animals vaccinated with UV-
DCs (Figure 5A). No proliferation was detected in lym-
phocytes from animals vaccinated with mock-electropo-
rated DCs or naïve animals (Figure 5A). Similar
proliferation was detected when splenocytes from mice
vaccinated with RNA-DCs were incubated with TC-1 or
ID8-E6/7 cells (Figure 5B), but no proliferation was
detected against control ID8 cells lacking E6 or E7, or L-
929 cells. This shows that the presence of HPV antigens
was critical for T cell proliferation (Figure 5B). Spleno-
cytes from all four groups of animals showed similar pro-
liferative response when stimulated with
phytohemagglutinin (not shown), indicating no func-
tional impairment.
We evaluated the frequency of tumor-reactive T cells
among splenocytes in each group of animals by IFN-γ
ELISPOT analysis. We used ID8-E6/E7 cells as target cells.
A significantly higher frequency of tumor-reactive IFN-γ
producing cells was found in spleens from animals vacci-
nated with RNA-DCs compared to animals vaccinated
with UV-DCs. No response was observed in splenocytes
from mock vaccinated or naïve animals (Figure 5C). Sim-
ilar response was seen in splenocytes from mice vacci-
nated with RNA-DCs incubated with TC-1 or ID8-E6/7
cells, while no response was observed against ID8 pr L-
929 cells (Figure 5D). Moreover, in the RNA vaccinated
group, IFN-γ producing cells were mainly CD8+ cells, since
immunodepletion of CD8+ cells in vivo decreased the
number of IFN-γ producing cells among isolated spleno-
cytes (Figure 5E).
Higher levels of cytotoxic lymphocyte activity were
detected in lymphocytes obtained from animals vacci-
nated with RNA-DCs relative to the UV-DCs group (Figure
5F). Moreover, CTL activity of splenocytes was abrogated
to control levels by immunodepletion of CD8+ cells in
vivo (Figure 5F). No lytic activity was observed when con-
trol ID8 cells expressing no E6 or E7, or L-929 cells were
used as target cells, confirming the specificity of the reac-
tion (not shown).
TC-1 tumors express HPV E6 and E7, offering the oppor-
tunity to quantify T cell responses against tumor-associ-
ated HPV epitopes through well-characterized tetramers
[37]. We compared the ability of RNA-DCs and UV-DCs
to generate T cell response against the H2-Db-restricted
HPV E7 epitope RAHYNIVTF [34]. A four-fold higher fre-
quency of tetramer-positive CD3+ CD8+ cells was detected
in splenocytes from animals vaccinated with RNA-DCs
compared to animals vaccinated with UV-DCs (Figure
5G).
Vaccination with RNA-DCs or UV-DCs
To test the efficacy of RNA-DCs and UV-DCs in vivo,
healthy mice were vaccinated with three injections of
RNA-DCs or UV-DCs prepared as above and administered
one week apart. Seven days after the last DC vaccination,
animals were challenged with flank subcutaneous TC-1
tumors. Tumor growth was significantly delayed in ani-
mals vaccinated with RNA-DCs as well as animals vacci-
nated with UV-DCs (Figure 6A). Although the difference
in tumor growth between mice vaccinated with RNA-DCs
and mice vaccinated with UV-DCs was not large, tumors
were significantly smaller in mice vaccinated with RNA-
DCs. Similar results were obtained in three independent
experiments.
Tumors from mice vaccinated with RNA-DCs as well as
from animals vaccinated with UV-DCs exhibited signifi-
cantly higher frequency of CD3+ tumor-infiltrating cells
relative to mice vaccinated with mock DCs. A higher fre-
quency of CD3+ tumor-infiltrating cells was detected in
animals vaccinated with RNA-DCs compared to animals
vaccinated with UV-DCs (Figure 6B, C). Finally, a higher
proportion of CD3+ cells were CD8+ in animals vaccinated
with RNA-DCs compared to animals vaccinated with UV-
DCs or mock DCs (Figure 6D).Journal of Translational Medicine 2008, 6:21 http://www.translational-medicine.com/content/6/1/21
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Antitumor immune response in vaccinated animals Figure 5
Antitumor immune response in vaccinated animals. (A) Proliferation of splenocytes from animals vaccinated with DCs electro-
porated with TC-1 RNA (RNA); pulsed with UV-irradiated TC-1 cells (UVB); mock-electroporated DCs (mock), or naïve ani-
mals. Splenocytes were stimulated in vitro with gamma-irradiated TC-1 cells for 5 days. Data are expressed as the mean ± SD 
(n = 5). RNA vs. UVB: p < 0.01; RNA vs. mock: p < 0.001; RNA vs. naive: p < 0.001; UVB vs. mock: p < 0.001; UVB vs. naive: p 
< 0.001 (ANOVA, Tukey-Kramer multicomparison post-test). (B) Proliferation of splenocytes from animals vaccinated with 
DCs electroporated with TC-1 cell RNA. Splenocytes were stimulated in vitro for 5 days with gamma-irradiated TC-1 cells, 
ID8-E6/E7 cells, ID8 cells carrying empty vector or L-929 cells. Data are expressed as the mean ± SD (n = 5). TC-1 vs. ID8-E6/
7: non significant (NS); TC-1 vs. ID8: p < 0.001; TC-1 vs. L-929: p < 0.001; ID8-E6/7 vs. ID8: p < 0.001; ID8-E6/7 vs. L-929: p < 
0.001. The experiment was repeated two times with similar results. (C) Quantification of IFN-γ producing tumor-reactive 
splenocytes by ELISPOT from the same experimental groups as in A. Data are expressed as the mean ± SD (n = 5). RNA vs. 
UVB: p < 0.05; RNA vs. mock: p < 0.005; RNA vs. naive: p < 0.005; UVB vs. mock: p < 0.005; UVB vs. naive: p < 0.005. (D) 
Quantification of IFN-γ producing tumor-reactive splenocytes by ELISPOT from the same experimental groups as in B. Data 
are expressed as the mean ± SD (n = 5). TC-1 vs. ID8-E6/7: non significant (NS); TC-1 vs. ID8: p < 0.001; TC-1 vs. L-929: p < 
0.001; ID8-E6/7 vs. ID8: p < 0.001; ID8-E6/7 vs. L-929: p < 0.001. (E) IFN-γ producing cells from splenocytes of RNA vacci-
nated animals upon CD8 immunodepletion. p < 0.01. (F) Cytotoxic assay using TC-1 cells as targets. Tumor cells were incu-
bated at 3:1 effector:target ratio with gradient-purified pooled splenic lymphocytes from animals vaccinated with DCs 
electroporated with TC-1 cell RNA (RNA) or pulsed with UV-irradiated TC-1 cells (UVB). Some groups were immunode-
pleted of CD8+ cells. Splenocytes were stimulated in vitro with gamma-irradiated TC-1 cells for 5 days. RNA vs. UVB: p < 0.05; 
Student's t-test. The experiment was repeated two times with similar results. (G) Frequency of anti-E7 CD8+ lymphocytes fol-
lowing DC vaccination. E7 tetramer-positive, CD3-gated CD8+ precursors were quantified in splenocytes from animals vacci-
nated with DCs pulsed with UVB-irradiated TC-1 cells (UVB) or DCs electroporated with TC-1 cell RNA (RNA), p < 0.05.
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Antitumor efficacy of RNA electroporated DCs Figure 6
Antitumor efficacy of RNA electroporated DCs. (A) Growth of flank TC-1 tumors in animals previously vaccinated with DCs 
electroporated with TC-1 cell RNA, UV-irradiated TC-1 cells, mock DCs or non-treated. Animals were challenged by injecting 
2 × 104 tumor cells. (n = 5 each group). Data are representative of three independent experiments with similar results. Day 30: 
RNA vs. UVB: p < 0.01; RNA vs. PBS: p < 0.01; RNA vs mock: p < 0.01; UVB vs. PBS: p < 0.01; UVB vs. mock: p < 0.01; PBS vs. 
mock: non significant. Mann-Whitney test. (B) CD3 and CD8 staining of tumors obtained from animals vaccinated with DCs 
electroporated with TC-1 cell RNA (RNA), DCs pulsed with UVB-irradiated TC-1 cells (UVB), or mock electroporated DCs. 
Magnification: 200X. (C) Counting of CD3 cells infiltrating TC-1 tumors. Experimental groups as in A. RNA vs. UVB: p < 0.001; 
RNA vs. mock: p < 0.001; UVB vs. mock: p < 0.001. Kruskal-Wallis non parametric ANOVA test. Dunn's multiple comparisons 
test. (D) Percentage of CD8+ among CD3+ cells infiltrating TC-1 tumors. Experimental groups as in A. RNA vs. UVB: p < 0.05; 
RNA vs. mock: p < 0.001; UVB vs. mock: NS (Kruskal-Wallis non parametric ANOVA test. Dunn's multiple comparisons test).
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Discussion
The present work addressed the relative efficacy of tumor
vaccines prepared with DCs either electroporated with
tumor RNA or with dead tumor cells. We used total RNA
from tumor cells isolated with a common laboratory
method and UVB irradiated tumor cells and optimized
the conditions to minimize difference in amount of
tumor cell material used to pulse DCs. We used the E7
MHC-I-restricted epitope RAHYNIVTF to quantify the
intensity of CD8+ T cell response against tumor-associated
antigens. The present results show that electroporation
with whole tumor cell RNA and pulsing with UVB-irradi-
ated tumor cells are both effective in eliciting antitumor
immune response, but RNA electroporation results in
more potent tumor vaccination. The efficacy of the vacci-
nation by RNA-electroporated DCs was dependent on the
presence of CD8+ cells, since in vivo depletion of these
cells abrogated the reported effect. Importantly, vaccina-
tion with RNA-electroporated DCs expressing E6 and E7
significantly enhanced infiltration of CD3+CD8+ into the
tumors.
To our knowledge this is the first direct comparison
between irradiated cells and whole RNA as a source of
whole tumor antigen to prepare DC based tumor vac-
cines. Because the same number of cells was used to derive
tumor antigen with both methodologies, the above find-
ings indicate that RNA electroporation is an efficient
methodology for loading DCs with tumor antigen. A pre-
vious report also found that apoptotic tumor cell pulsing
is not an efficient approach to tumor vaccination [38].
Several reasons may account for our findings. First, anti-
gen up-take may be less efficient with pulsing dying cells
compared to RNA electroporation. Since UVB irradiation
has been shown to result in a mixed population of apop-
totic and necrotic tumor cells [16], it is possible that either
process leads to degradation of important antigens [39],
resulting in suboptimal antigen processing or presenta-
tion. Second, apoptotic DNA may bind to MHC class mol-
ecules and interfere with antigen presentation [40]. Third,
although non-viral methods of DNA transfection of DCs
are inefficient, the efficiency of gene transfer with RNA
electroporation resembles that of transfection with
recombinant viruses [41]. Finally, another advantage of
RNA transfer of DC over pulsing DC with protein antigens
is that endogenously synthesized antigens have better
access to the class I MHC pathway [42].
It is noteworthy to comment that different maturation
protocols can modify the capability of DCs to effectively
present antigens upon RNA electroporation. In a series of
elegant studies, Zobylawski et al., have shown that human
DCs treated with a maturation cocktail formulated with
TNF, IL-1β, IFN-γ, prostaglandin E2, and the Toll like
receptor (TLR) 8 agonist R848 were able to generate an
efficient immune response upon RNA electroporation;
while addition of the TLR3 ligand poly(I:C) to the matu-
ration cocktail rendered DCs unable to express proteins
from electroporated RNA [43]. Indeed, the formulation of
appropriate maturation cocktails is one of the challenges
that faces the generation of effective DC-based vaccines
for clinical use [44]. Thus, the use of different activation
protocols might have produced different results in our
studies. Further, since in our studies we used murine bone
marrow-derived DCs, they may not directly translate to
human monocyte-derived dendritic cells used for clinical
studies. Additional studies with human monocyte-
derived dendritic cells must be performed in order to
determine the clinical relevance of our findings. Finally, it
should be noted that our work compared RNA to dead
tumor cells and our findings on superiority of RNA as a
source of whole tumor antigen may not be relevant to
alternate methods of preparing whole tumor cell protein,
such as tumor lysates [45], which may preserve tumor
antigens or do not interfere with antigen presentation.
Conclusion
Collectively, our data suggest that electroporation of
whole tumor RNA represents a direct and effective way of
delivering tumor antigen to DCs ex vivo. Coupled with
the easier procurement of tumor RNA compared to the
generation of tumor cell lines, these findings suggest that
RNA electroporation should be a preferred method of
loading DCs with whole tumor antigen in clinical trials.
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